Australia is on the verge of a new era of growth in the life sciences. Given the number of investment opportunities it has generated in recent years, this discipline is one of the country’s backbone sectors. These investments are primarily in real estate, which has been thriving in the country for the past 18 months to say the least.
Furthermore, pharmaceutical corporations have been in the spotlight as the expansion of their capacities, including distribution, manufacturing, and R&D, is poised to become a trend.
This advancement is strongly supported by the Australian government, which has continued to support the advancement of life sciences and recognizes their importance to the country’s economy.
It is important to note that, like other sectors, the life sciences were severely impacted by the novel COVID-19 pandemic.
To that end, while the Australian government continues to exert relentless efforts to restore the country’s general economy to full stability and thriving, they have also exerted equal efforts to restore the lost glory of the country’s life science industries, which are unquestionably one of its key business drivers.
This CBRE Research report on the country’s life sector focuses on the investable universe of life sciences. It also highlights sector trends and movement, corporate real estate strategies, and the opportunities created as a result.
